TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04166955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Physical Activity through mobile application
Description: Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
Study: NCT03520426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Votiva RF
Description: The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Votiva RF
Description: The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
Study: NCT01401101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCM
Description: Care Manager (CM) intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MEU
Description: The MEU condition consists of only the clinician education and patient screening without written feedback.
Study: NCT02238236

Intervention type: DRUG
Intervention: Alesion®
Description: Dry Syrup
Study: NCT01730001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late intubation
Study: NCT01228149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with preoperative Diamox/DexaEDO treatment
Description: Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with preoperative Cosopt S treatment
Description: Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
Study: NCT04142840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
Study: NCT03441516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfoatirin® Tab. + Aripezil® Tab.
Description: Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripezil® Tab.
Description: Donepezil 10 mg Oral Tablet qd for 24 weeks
Study: NCT02455440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and sevoflurane
Study: NCT00857116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
Study: NCT02345629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heat Pain Sensory Testing
Description: Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
Study: NCT02895152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
Study: NCT03467139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal breathing exercise
Description: Deep Breathing Exercise
Study: NCT04074629

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnosis, skin volatile organic compounds (VOCs)
Description: The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis
Study: NCT03857750

Intervention type: DRUG
Intervention: Rocuronium
Description: 0.6 mg/kg

Intervention type: DRUG
Intervention: Rocuronium
Description: 0.6 mg/kg
Study: NCT02315430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT01682486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP ETT (Bactiguard)
Description: Ventilation of surgery patients during anesthesia using BIP ETT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard ETT
Description: Ventilation of surgery patients during anesthesia using standard ETT
Study: NCT01890135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zibotentan (ZD4054)
Description: 10 mg
Study: NCT00857116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
Study: NCT01890135

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zibotentan (ZD4054)
Description: 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: randomized double blind

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: randomized double blind
Study: NCT03995121

Intervention type: RADIATION
Intervention: [11C]APP311
Description: It has been shown that \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

Intervention type: RADIATION
Intervention: [11C]APP311
Description: It has been shown that \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

Intervention type: RADIATION
Intervention: [11C]APP311
Description: It has been shown that \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
Study: NCT04366102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation with soft tissue therapy
Description: Multisensory stimulation with soft tissue therapy will be given. Multisensory stimulation consists of Auditory, vestibular, tactile, olfactive, oromotor, Visual, and Kinesthetic stimulation. Soft tissue therapy consists of stroking, effleurage, fingertip kneading, tapping, and skin rolling will be given. Total intervention will be given for 30 min. 5 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine hospital care
Description: Routine hospital care will be given to the preterm neonates
Study: NCT03521934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04915430

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Study: NCT04592601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: S.L.I.M.M.S. Procedure
Description: Combined Gastric Bypass with Vertical Sleeve Gastrectomy
Study: NCT02115893

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrate
Study: NCT01656005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone
Description: 2 puffs bid for final week (week 6) of each treatment arm
Study: NCT04105140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo (24 IU)
Study: NCT03149445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesofensine/Metoprolol
Description: Study medication will be administered for 91 days.
Study: NCT01656005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone
Description: 2 puffs bid for final week (week 6) of each treatment arm
Study: NCT02115893

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study: NCT00371215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin
Description: 1000 U/mL applied topically
Study: NCT01939977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
Study: NCT00477243

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 8 questionnaires will take about 40 minutes to complete.
Study: NCT01500421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TH - Endovascular alone (Alsius®, Zoll, USA)
Description: Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)
Description: Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)
Description: Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
Study: NCT02269982

Intervention type: DEVICE
Intervention: AR-v7 assays
Study: NCT03733249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid is administered to treat chronic graft versus host disease

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rivogenlecleucel
Description: donor T-cells modified with iCasp safety switch
Study: NCT02447952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Faros Sensor (FS) and LifeInsight Hub
Description: Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Fix electrode patch
Description: The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Measure of Speech (Core Phase Only)
Description: Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
Study: NCT03177954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Oriented Discharge Summary
Description: Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
Study: NCT01637844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
Study: NCT04106011

Intervention type: DRUG
Intervention: Gabapentin
Description: Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).

Intervention type: DIAGNOSTIC_TEST
Intervention: BTACT
Description: Cognition measure: Brief Test of Adult Cognition by Telephone

Intervention type: DIAGNOSTIC_TEST
Intervention: BPI
Description: Pain severity and interference at baseline using the Brief Pain Inventory

Intervention type: DIAGNOSTIC_TEST
Intervention: HADS
Description: Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: SLP9
Description: Assessment of Sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: NPSI
Description: Assessment of neuropathic components
Study: NCT01674972

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral intake of 75 g glucose after overnight fast

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: Oral intake of 75 g glucose after overnight fast
Study: NCT01939977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcifediol
Description: 5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
Study: NCT03931590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Omaveloxolone
Description: \[14C\]-Omaveloxolone 50 mg capsules
Study: NCT05823428

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Augmentation with subacromial bursa + acromioplasty
Description: Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff debridement + acromioplasty
Description: Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
Study: NCT01501162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis, alcohol, probiotics
Description: 7 days of probiotics (1500 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alcohol, hepatitis, Placebo
Description: Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
Study: NCT01215786

Intervention type: DRUG
Group type: OTHER
Intervention: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
Description: One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol ophthalmic solution 0.5%
Description: One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-207281 vehicle ophthalmic solution (Placebo)
Description: One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
Study: NCT01919086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
Study: NCT06059274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical serum
Description: Participants are asked to apply the topical serum twice daily for 84 days.
Study: NCT01004874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (XRT)
Description: Standard radiation therapy for approximately 6.5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
Study: NCT04797494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acrylic removable appliance
Description: Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating.
Study: NCT03333434

Intervention type: DEVICE
Group type: OTHER
Intervention: Carbon Ankle Seven spring (A7 - Otto Bock, Germany)

Intervention type: DEVICE
Group type: OTHER
Intervention: Carbon Ankle Seven spring (A7 - Otto Bock, Germany)

Intervention type: DEVICE
Group type: OTHER
Intervention: Hinged AFO

Intervention type: DEVICE
Group type: OTHER
Intervention: Hinged AFO
Study: NCT01310192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluourine-18 Fluoromethylcholine PET/CT Imaging
Description: Single-dose Study
Study: NCT03988790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOC analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry.
Study: NCT04085991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-PSMA-1095 Radioligand Therapy (RLT)
Description: Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
Study: NCT02809846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quell

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Quell
Study: NCT02513394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Adjuvant Endocrine Therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Adjuvant Endocrine Therapy
Study: NCT03593564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KINDER
Description: KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.